Pharmamarketeer
wet- en regelgeving

Andexxa will go nationwide with FDA nod on Portola’s commercial production of the bleeding antidote

3 januari 2019
FiercePharma

Portola will finally see the commercial release of its universal bleeding reversal agent Andexxa, a milestone not only for the biotech but also for Pfizer and Bristol-Myers Squibb, as well as Bayer and Johnson & Johnson, whose blood thinners rely on it as a bleeding antidote.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)